Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28078872 | 0.79 | PIN1 (0.56) | GAANPC1RAB9AMAPK13MAPK12 | |
| SCHEMBL18585937 | 0.79 | GAA (0.49) | GAANPC1RAB9AMAPK13MAPK12 | |
| SCHEMBL17810232 | 0.79 | MAPT (0.55) | NPC1RAB9AALDH1A1MAPTHPGD | |
| SCHEMBL11314796 | 0.75 | BTK (0.43) | GAANPC1RAB9AMAPK13MAPK12 | |
| SCHEMBL1719774 | 0.75 | MAPK13 (0.49) | NPC1RAB9AMAPK13MAPK12MAPK11 | |
| SCHEMBL1720364 | 0.74 | CYP1A2 (0.55) | NPC1RAB9AMAPK13MAPK12MAPK11 | |
| SCHEMBL2899324 | 0.72 | METAP2 (0.54) | GAANPC1RAB9AALDH1A1MAPT | |
| SCHEMBL1720665 | 0.71 | TRPV1 (0.49) | TNKS2NPY5RSCN2A | |
| SCHEMBL27741615 | 0.71 | MAPK14 (0.50) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL27741601 | 0.71 | MAPK13 (0.57) | NPC1RAB9AMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105753788-A | Preparation method of 1-substituted-2-phenyl-4-idoimidazole | 西南科技大学 | 2016-07-13 | — | — | CN | claimed |
| CN-107001375-B | 6, 7-dihydropyrazolo [1,5-a ] pyrazin-4 (5H) -one compounds and their use as negative allosteric modulators of MGLUR2 receptors | 詹森药业有限公司 | 2020-06-09 | — | — | CN | disclosed |
| EP-3227295-B1 | 6,7-DIHYDROPYRAZOLO[1,5- ]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-20 | — | — | EP | disclosed |
| US-10072014-B2 | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of MGLUR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-11 | — | — | US | disclosed |
| US-20170369493-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN-CILAG, S.A. (ES) | 2017-12-28 | — | — | US | disclosed |
| EP-3227295-A1 | 6,7-DIHYDROPYRAZOLO[1,5- ]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceutica NV (BE) | 2017-10-11 | — | — | EP | disclosed |
| CN-105753788-A | Preparation method of 1-substituted-2-phenyl-4-idoimidazole | 西南科技大学 | 2016-07-13 | — | — | CN | disclosed |
| WO-2016087487-A1 | 6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369493-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | GAA 3925/4885NPC1 1715/4885RAB9A 1924/4885 |
| US-10072014-B2 | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of MGLUR2 receptors | GRM2, GRM5, GRM1 | GAA 3925/4885NPC1 1715/4885RAB9A 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.